- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01114217
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Indien
- Clinical Trial Site
-
Secunderabad, Andhra Pradesh, Indien
- Clinical Trial Site
-
-
Assam
-
Guwahati, Assam, Indien
- Clinical Trial Site
-
-
Karnataka
-
Bangalore, Karnataka, Indien, 560002
- Clinical Trial Site
-
Bangalore, Karnataka, Indien, 560054
- Clinical Trial Site
-
-
Maharashtra
-
Aurangabad, Maharashtra, Indien
- Clinical Trial Site
-
Nagpur, Maharashtra, Indien
- Clinical Trial Site
-
Nashik, Maharashtra, Indien
- Clinical Trial Site
-
Pune, Maharashtra, Indien
- Clinical Trial Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien
- Clinical Trial Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indien
- Clinical Trial Site
-
Madurai, Tamil Nadu, Indien
- Clinical Trial Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Indien, 226003
- Clinical Trial Site
-
Lucknow, Uttar Pradesh, Indien
- Clinical Trial Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
- Clinical Trial Site
-
-
New Brunswick
-
Saint John, New Brunswick, Kanada
- Clinical Trial Site
-
-
Ontario
-
London, Ontario, Kanada
- Clinical Trial Site
-
Thornhill, Ontario, Kanada
- Clinical Trial Site
-
Vaughan, Ontario, Kanada
- Clinical Trial Site
-
-
Quebec
-
Pointe-Claire, Quebec, Kanada
- Clinical Trial Site
-
-
-
-
-
Daugavpils, Lettland
- Clinical Trial Site
-
Riga, Lettland, LV-1002
- Clinical Trial Site
-
Riga, Lettland, LV-1005
- Clinical Trial Site
-
Riga, Lettland, LV-1006
- Clinical Trial Site
-
Riga, Lettland, LV-1010
- Clinical Trial Site
-
Valmiera, Lettland
- Clinical Trial Site
-
Ventspils, Lettland, LV-3601
- Clinical Trial Site
-
Ventspils, Lettland
- Clinical Trial Site
-
-
-
-
-
Białystok, Polen
- Clinical Trial Site
-
Sopot, Polen
- Clinical Trial Site
-
Warszawa, Polen
- Clinical Trial Site
-
Wrocław, Polen
- Clinical Trial Site
-
-
-
-
-
Bekescsaba, Ungarn
- Clinical Trial Site
-
Gyula, Ungarn
- Clinical Trial Site
-
Komárom, Ungarn
- Clinical Trial Site
-
Szekszárd, Ungarn
- Clinical Trial Site
-
Vác, Ungarn
- Clinical Trial Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten
- Clinical Trial Site
-
Mobile, Alabama, Vereinigte Staaten
- Clinical Trial Site
-
Montgomery, Alabama, Vereinigte Staaten, 36106
- Clinical Trial Site
-
Montgomery, Alabama, Vereinigte Staaten, 36116
- Clinical Trial Site
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85032
- Clinical Trial Site
-
Phoenix, Arizona, Vereinigte Staaten, 85015
- Clinical Trial Site
-
Tucson, Arizona, Vereinigte Staaten, 85710
- Clinical Trial Site
-
Tucson, Arizona, Vereinigte Staaten, 85712
- Clinical Trial Site
-
-
California
-
Anaheim, California, Vereinigte Staaten
- Clinical Trial Site
-
Bakersfield, California, Vereinigte Staaten
- Clinical Trial Site
-
Buena Park, California, Vereinigte Staaten
- Clinical Trial Site
-
Colton, California, Vereinigte Staaten
- Clinical Trial Site
-
Los Angeles, California, Vereinigte Staaten, 90036
- Clinical Trial Site
-
Los Angeles, California, Vereinigte Staaten, 90057
- Clinical Trial Site
-
Los Angeles, California, Vereinigte Staaten
- Clinical Trial Site
-
Mission Hills, California, Vereinigte Staaten
- Clinical Trial Site
-
Orange, California, Vereinigte Staaten
- Clinical Trial Site
-
San Diego, California, Vereinigte Staaten, 92103
- Clinical Trial Site
-
San Diego, California, Vereinigte Staaten, 92123
- Clinical Trial Site
-
San Diego, California, Vereinigte Staaten, 92121
- Clinical Trial Site
-
-
Colorado
-
Pueblo, Colorado, Vereinigte Staaten
- Clinical Trial Site
-
-
Connecticut
-
Bristol, Connecticut, Vereinigte Staaten
- Clinical Trial Site
-
Groton, Connecticut, Vereinigte Staaten
- Clinical Trial Site
-
-
Florida
-
Boynton Beach, Florida, Vereinigte Staaten, 33426
- Clinical Trial Site
-
Boynton Beach, Florida, Vereinigte Staaten, 33472
- Clinical Trial Site
-
Clearwater, Florida, Vereinigte Staaten, 33759
- Clinical Trial Site
-
Clearwater, Florida, Vereinigte Staaten, 33756
- Clinical Trial Site
-
Hialeah, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Holiday, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Inverness, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Margate, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Miami, Florida, Vereinigte Staaten, 33126
- Clinical Trial Site
-
Miami, Florida, Vereinigte Staaten, 33143
- Clinical Trial Site
-
Miami, Florida, Vereinigte Staaten, 33144
- Clinical Trial Site
-
Miami, Florida, Vereinigte Staaten, 33175
- Clinical Trial Site
-
Miami, Florida, Vereinigte Staaten, 33135
- Clinical Trial Site
-
Miami Lakes, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Naples, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Vero Beach, Florida, Vereinigte Staaten
- Clinical Trial Site
-
West Palm Beach, Florida, Vereinigte Staaten
- Clinical Trial Site
-
Zephyrhills, Florida, Vereinigte Staaten
- Clinical Trial Site
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Clinical Trial Site
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Clinical Trial Site
-
Atlanta, Georgia, Vereinigte Staaten, 30312
- Clinical Trial Site
-
Decatur, Georgia, Vereinigte Staaten
- Clinical Trial Site
-
Dublin, Georgia, Vereinigte Staaten
- Clinical Trial Site
-
Sandy Springs, Georgia, Vereinigte Staaten
- Clinical Trial Site
-
Stockbridge, Georgia, Vereinigte Staaten
- Clinical Trial Site
-
-
Illinois
-
Aurora, Illinois, Vereinigte Staaten
- Clinical Trial Site
-
Chicago, Illinois, Vereinigte Staaten, 60616
- Clinical Trial Site
-
Skokie, Illinois, Vereinigte Staaten, 60076
- Clinical Trial Site
-
Skokie, Illinois, Vereinigte Staaten
- Clinical Trial Site
-
Springfield, Illinois, Vereinigte Staaten
- Clinical Trial Site
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten
- Clinical Trial Site
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten
- Clinical Trial Site
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten
- Clinical Trial Site
-
Hollywood, Maryland, Vereinigte Staaten
- Clinical Trial Site
-
-
Michigan
-
Bay City, Michigan, Vereinigte Staaten, 48706
- Clinical Trial Site
-
Bay City, Michigan, Vereinigte Staaten
- Clinical Trial Site
-
Wyoming, Michigan, Vereinigte Staaten
- Clinical Trial Site
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten
- Clinical Trial Site
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten
- Clinical Trial Site
-
-
New Jersey
-
Lawrenceville, New Jersey, Vereinigte Staaten
- Clinical Trial Site
-
Neptune, New Jersey, Vereinigte Staaten
- Clinical Trial Site
-
Plainsboro, New Jersey, Vereinigte Staaten
- Clinical Trial Site
-
Voorhees, New Jersey, Vereinigte Staaten
- Clinical Trial Site
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten
- Clinical Trial Site
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten
- Clinical Trial Site
-
New York, New York, Vereinigte Staaten, 10038
- Clinical Trial Site
-
-
North Carolina
-
Raleigh, North Carolina, Vereinigte Staaten
- Clinical Trial Site
-
Winston-Salem, North Carolina, Vereinigte Staaten
- Clinical Trial Site
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten
- Clinical Trial Site
-
Carlisle, Ohio, Vereinigte Staaten
- Clinical Trial Site
-
Cincinnati, Ohio, Vereinigte Staaten, 45224
- Clinical Trial Site
-
Cincinnati, Ohio, Vereinigte Staaten, 45242
- Clinical Trial Site
-
Columbus, Ohio, Vereinigte Staaten, 43231
- Clinical Trial Site
-
Marion, Ohio, Vereinigte Staaten, 43302
- Clinical Trial Site
-
Marion, Ohio, Vereinigte Staaten
- Clinical Trial Site
-
Mentor, Ohio, Vereinigte Staaten
- Clinical Trial Site
-
Middletown, Ohio, Vereinigte Staaten
- Clinical Trial Site
-
Zanesville, Ohio, Vereinigte Staaten
- Clinical Trial Site
-
-
Oklahoma
-
Norman, Oklahoma, Vereinigte Staaten
- Clinical Trial Site
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, Vereinigte Staaten
- Clinical Trial Site
-
Levittown, Pennsylvania, Vereinigte Staaten
- Clinical Trial Site
-
-
South Carolina
-
Columbia, South Carolina, Vereinigte Staaten
- Clinical Trial Site
-
Greer, South Carolina, Vereinigte Staaten
- Clinical Trial Site
-
Myrtle Beach, South Carolina, Vereinigte Staaten
- Clinical Trial Site
-
North Charleston, South Carolina, Vereinigte Staaten
- Clinical Trial Site
-
-
South Dakota
-
Rapid City, South Dakota, Vereinigte Staaten
- Clinical Trial Site
-
-
Texas
-
Arlington, Texas, Vereinigte Staaten
- Clinical Trial Site
-
Dallas, Texas, Vereinigte Staaten
- Clinical Trial Site
-
Houston, Texas, Vereinigte Staaten, 77030
- Clinical Trial Site
-
Houston, Texas, Vereinigte Staaten, 77074
- Clinical Trial Site
-
Houston, Texas, Vereinigte Staaten
- Clinical Trial Site
-
Laredo, Texas, Vereinigte Staaten
- Clinical Trial Site
-
Longview, Texas, Vereinigte Staaten
- Clinical Trial Site
-
San Antonio, Texas, Vereinigte Staaten, 78205
- Clinical Trial Site
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Clinical Trial Site
-
San Antonio, Texas, Vereinigte Staaten
- Clinical Trial Site
-
San Antonio, Texas, Vereinigte Staaten, 78215
- Clinical Trial Site
-
-
Utah
-
Orem, Utah, Vereinigte Staaten
- Clinical Trial Site
-
-
Virginia
-
Chesapeake, Virginia, Vereinigte Staaten
- Clinical Trial Site
-
Norfolk, Virginia, Vereinigte Staaten
- Clinical Trial Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria include:
- Participants who completed participation in study AMAG-FER-IDA-301 [NCT01114139]
- Female participants of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study
Key Exclusion Criteria include:
- Experienced a serious adverse event (SAE) related to ferumoxytol in study AMAG-FER-IDA-301
- Female participants who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Ferumoxytol
Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139].
Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit).
Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV).
The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1.
The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
|
IV Ferumoxytol
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol
Zeitfenster: TP Baseline (Day 1), TP Week 5
|
Mean change in hemoglobin from TP Baseline (Day 1) to TP Week 5 following the first dose of ferumoxytol was calculated as: Hemoglobin Change = Hemoglobin (TP Week 5) - Hemoglobin (TP Baseline) TP Baseline was the most recent value measured on/after the screening or the closest monthly evaluation visit prior to Day 1 dosing of Course 1. Change from Baseline used an imputed value of 0 for missing values at the post-baseline visit. |
TP Baseline (Day 1), TP Week 5
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Mean Change In Hemoglobin Following Each Course Of Ferumoxytol From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol After The First Course
Zeitfenster: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Mean change in hemoglobin from TP Baseline to TP Week 5 following each course of ferumoxytol after the first course was calculated for each participant as: Hemoglobin Change = Hemoglobin (TP Week 5) - Hemoglobin (TP Baseline) The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1. The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered. |
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Percentage Of Participants With An Increase In Hemoglobin ≥2.0 g/dL At Any Time From TP Baseline To TP Week 5
Zeitfenster: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Proportion of participants with an increase in hemoglobin ≥2.0 g/dL at any time from TP Baseline to TP Week 5 following each course of ferumoxytol.
The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1.
The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered.
|
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Percentage Of Participants Who Achieved A Hemoglobin Level ≥12.0 g/dL At Any Time From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol
Zeitfenster: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Proportion of participants who achieved a hemoglobin level ≥12.0 g/dL at any time from TP Baseline to TP Week 5 following each course of ferumoxytol.
The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1.
The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered.
|
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Mean Change In TSAT Following Each Course Of Ferumoxytol From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol
Zeitfenster: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Mean change in TSAT from TP Baseline to TP Week 5 following each course of ferumoxytol.
|
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Patient-reported Outcome Measure: Mean Change In Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Questionnaire From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol
Zeitfenster: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
The FACIT-Fatigue questionnaire is a 13-item questionnaire designed and validated to specifically assess the presence and impact of treatment on fatigue and related symptoms, such as tiredness, on health-related quality of life in anemic participants with cancer. The questionnaire has 13 items, each measured on a 4-point Likert scale. Scoring ranges from 0 (the most fatigued) to 52 (the least fatigued) points, with higher scores representing better functioning or less fatigue. Mean change in FACIT-Fatigue questionnaire from TP Baseline to TP Week 5 following each course of ferumoxytol was calculated as: FACIT-Fatigue Score Change = FACIT-Fatigue Score (Week 5) - FACIT-Fatigue Score (Baseline). TP Baseline was the most recent value measured on/after the screening or the closest monthly evaluation visit prior to Day 1 dosing in each course. If the TP Week 5 FACIT-Fatigue Score value was missing, the change from TP Baseline was conservatively imputed as zero. |
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Time To Hemoglobin Increase Of ≥2.0 g/dL Or To A Hemoglobin Level Of ≥12.0 g/dL From Baseline
Zeitfenster: TP Baseline (Day 1) up to TP Week 5 for Courses 1, 2, and 3
|
Days to event was defined as the days from Baseline to the first time the participant met the criteria. Participants without any post-Baseline study visits were not included in this analysis. The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1. The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered. |
TP Baseline (Day 1) up to TP Week 5 for Courses 1, 2, and 3
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AMAG-FER-IDA-303
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Eisenmangelanämie
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... und andere MitarbeiterRekrutierungMitochondriale Erkrankungen | Retinitis pigmentosa | Myasthenia gravis | Eosinophile Gastroenteritis | Multiple Systematrophie | Leiomyosarkom | Leukodystrophie | Analfistel | Spinozerebelläre Ataxie Typ 3 | Friedreich Ataxie | Kennedy-Krankheit | Lyme-Borreliose | Hämophagozytische Lymphohistiozytose | Spinozerebelläre... und andere BedingungenVereinigte Staaten, Australien
Klinische Studien zur Ferumoxytol
-
Michael IvNational Cancer Institute (NCI)ZurückgezogenNeubildung des Gehirns im KindesalterVereinigte Staaten
-
Massachusetts General HospitalAbgeschlossenPapilläres Karzinom der Schilddrüse | Metastasierter medullärer Schilddrüsenkrebs | Lymphknotenmetastasen bei follikulärem SchilddrüsenkrebsVereinigte Staaten
-
Allegheny Singer Research Institute (also known...Aktiv, nicht rekrutierendLebertumoren | Hepatozelluläres Karzinom | Lebermetastasen | Leberkrebs | Leberkarzinom | Leberzellkrebs | Leberzirrhose | Leberkrebs | LeberatrophieVereinigte Staaten
-
OHSU Knight Cancer InstituteOregon Health and Science University; Radiological Society of North AmericaBeendetRektumkarzinom im Stadium III AJCC v7 | Rektumkarzinom im Stadium IIIA AJCC v7 | Stadium IIIB Rektumkarzinom AJCC v7 | Rektumkarzinom im Stadium IIIC AJCC v7 | Lokal fortgeschrittenes RektumkarzinomVereinigte Staaten
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; National... und andere MitarbeiterRekrutierungAdenokarzinom des Pankreas | Familiärer Bauchspeicheldrüsenkrebs | Intraduktales papillär-muzinöses Neoplasma der BauchspeicheldrüseVereinigte Staaten
-
Michael IvAbgeschlossenGehirnverletzung | Hirntumor | Hirntumore | Primäre Neoplasie des Gehirns | Ischämischer zerebrovaskulärer Unfall | Degenerative Störung des zentralen Nervensystems | Infektionskrankheit des zentralen Nervensystems | Vaskuläre Malformation des zentralen Nervensystems | Hämorrhagischer zerebrovaskulärer...Vereinigte Staaten
-
OHSU Knight Cancer InstituteOregon Health and Science University; AMAG Pharmaceuticals, Inc.ZurückgezogenNeoplasma des Gehirns
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityZurückgezogenSpeiseröhrenkrebs im Stadium IIB AJCC v7 | Speiseröhrenkrebs im Stadium III AJCC v7 | Speiseröhrenkrebs im Stadium IIIA AJCC v7 | Speiseröhrenkrebs im Stadium IIIB AJCC v7 | Speiseröhrenkrebs im Stadium IIIC AJCC v7
-
The First Affiliated Hospital with Nanjing Medical...Rekrutierung
-
Jason GagliaHarvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious...Unbekannt